Pawel Teterycz
Overview
Explore the profile of Pawel Teterycz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sobczuk P, Filipowicz P, Lamparski L, Kosela-Paterczyk H, Teterycz P, Kozak K, et al.
Sci Rep
. 2025 Feb;
15(1):5247.
PMID: 39939795
Trabectedin is a chemotherapeutic agent that has shown activity in the treatment of patients with soft tissue sarcomas after failure of anthracycline-based therapy and the best results were recorded in...
2.
Chwialkowska V, Slowinska M, Platkowska A, Kania J, Parciak K, Czarnecka A, et al.
Exp Ther Med
. 2024 Dec;
29(1):15.
PMID: 39624595
Superficial mucoceles (SM) are small, benign, translucent vesicles, which develop in the oral mucosa, mainly on the lower lip, due to a rupture of minor salivary gland ducts and the...
3.
Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova G, Kandolf L, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39517999
Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab...
4.
Mandala M, Ferrari A, Brecht I, Suijkerbuijk K, Maschke L, Giannarelli D, et al.
Eur J Cancer
. 2024 Sep;
211:114305.
PMID: 39236557
Background: Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine outcomes of...
5.
Teterycz P, Szostakowski B, Rosinska M, Krzyzanowska K, Rutkowski P
Eur J Surg Oncol
. 2024 Aug;
50(10):108604.
PMID: 39151309
1 BACKGROUND: COVID-19 pandemic had a major impact on the healthcare system globally. This work aims to evaluate COVID-19 impact on local treatment in bone sarcoma treated in a single,...
6.
Czarnecka A, Chmiel P, Blonski P, Switaj T, Rogala P, Falkowski S, et al.
J Chemother
. 2024 Aug;
:1-12.
PMID: 39115147
Our study was carried out to define the efficacy of treatment with sequential chemotherapy lines in patients with epithelioid sarcoma (ES) at referral centres for sarcoma. From 1998 to 2023,...
7.
Czarnecka A, Chmiel P, Blonski P, Switaj T, Rogala P, Falkowski S, et al.
J Chemother
. 2024 Jul;
:1-12.
PMID: 38973299
Clear cell sarcoma is an ultra-rare chemoresistant subtype of soft tissue sarcoma. This retrospective analysis aimed to clarify the efficacy of palliative chemotherapy in CCS by assessing response rates, progression-free...
8.
Piorek A, Pluzanski A, Knetki-Wroblewska M, Winiarczyk K, Tabor S, Teterycz P, et al.
BMC Cancer
. 2024 Jun;
24(1):686.
PMID: 38840114
Objective: Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal management poses a considerable challenge....
9.
Piorek A, Pluzanski A, Teterycz P, Tabor S, Winiarczyk K, Knetki-Wroblewska M, et al.
Thorac Cancer
. 2024 Mar;
15(11):878-883.
PMID: 38429910
Background: Primary tracheal tumors are very rare and the literature on this subject is limited. The most common histological type of primary tracheal tumors is squamous cell carcinoma (SCC), followed...
10.
Zietek M, Teterycz P, Wierzbicki J, Jankowski M, Las-Jankowska M, Zegarski W, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345002
Background: In melanoma treatment, an approach following positive sentinel lymph node biopsy (SLNB) has been recently deescalated from completion lymph node dissection (CLND) to active surveillance based on phase III...